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 The fungus Cunninghamella elegans can metabolise JWH-018, JWH-073 and 
AM2201
 The majority of the metabolites was produced via phase I metabolism
 The fungal metabolites were found to be in good agreement with the human 
metabolites
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Being marketed as “legal” smoking blends or mixtures, synthetic cannabinoids are abused 2
widely owing to its cannabis-like effect. Due to the rapid introduction of new generation 3
analogues of synthetic cannabinoids to escape from legislative/judicial control, the 4
investigation of the metabolic pathways of these substances is of particular importance for 5
drug control, abstinence and forensic toxicology purposes. In this study, the in vitro6
metabolism of JWH-018, JWH-073 and AM2201 by the fungus Cunninghamella elagans has 7
been investigated with the purpose of validating its potential as a complementary model for 8
investigating synthetic cannabinoid metabolism. JWH-018, JWH-073 and AM2201 were 9
incubated for 72 h with C. elegans. Detection of metabolites was based on liquid 10
chromatography – tandem mass spectrometry and high resolution mass spectrometry analysis. 11
C. elegans was found capable of producing the majority of the phase I metabolites observed 12
in earlier in vitro and in vivo mammalian studies as a result of monohydroxylation, 13
dihydroxylation, carboxylation, dehydrogenation, ketone formation, dihydrodiol formation, 14
dihydrodiol formation with N-dealkylation and combinations thereof. C. elegans can thus be a 15
useful and economic model for studying synthetic cannabinoid metabolism.16
17




















Abusive consumption of synthetic cannabinoids that are agonists at cannabinoid CB128
receptors has been commonly reported since 2008 [1]. Usually sold as herbal blends or29
research chemicals in powder, synthetic cannabinoids mimic psychoactive effects of cannabis. 30
However, unlike cannabis some synthetic cannabinoids are reported to be full agonists and 31
thus create more serious public health issues [2]. When a synthetic cannabinoid is scheduled 32
due to increased prevalence and health concerns, new molecules with similar or even stronger 33
psychoactive effects are synthesized by slight structural modifications to bypass the laws [3, 34
4]. The lack of metabolism data of these new psychoactive molecules together with the lack 35
of reference standards has made optimized detection in biological matrices, especially urine,36
difficult.37
Due to rapid changes in product composition and continuous emergence of new 38
compounds, identifying the unique fingerprint of drug metabolites is of vital importance for 39
forensic-toxicological, clinical-toxicological and doping analysis. Several in vivo and in vitro40
models are being used to identify metabolites of synthetic cannabinoids. In vivo studies 41
involving the researcher himself administering drug have been reported [5]. Despite the 42
reliability of data obtained from such experiments, the adverse effects of these drugs are 43
unknown and due to both health and ethical reasons it is difficult to perform in vivo human 44
excretion studies to investigate the metabolism.45
Other in vivo animal systems such as mouse, rat, and primates can be used as 46
alternatives to human administration in metabolism studies. Unfortunately these models suffer 47
from a number of limitations such as ethical constraints, cost of experimental models, time 48
that must be spend on breeding animals etc. [6]. Moreover species differences in the excretory 49
pathway may make the extrapolation from experimental animals to humans difficult [7]. 50
Recently in vivo chimeric mouse models based upon the transplantation of primary human 51
hepatocytes in uPA-SCID mice that suffer from a transgene-induced liver disease have been 52










evaluated. This model proved to be an efficient alternative for human administration studies 53
for the investigation of steroid metabolism and was recently used to reveal both phase I and 54
phase II metabolism of synthetic cannabinoids, JWH-200 and JWH-122 [8-10]. Although the 55
chimeric mouse is a promising model with respect to the array of metabolic pathways, the 56
cost and complexity involved in the development of such a model with a high level of 57
hepatocyte repopulation, low amount of urine that can be collected and the concentrated 58
mouse urine matrix are some inherent limitations [10, 11].59
In vitro platforms like perfused liver, hepatocytes or human liver microsomes are 60
other valuable models for the elucidation of drug metabolism [6]. In particular, primary 61
human hepatocytes give the closest metabolic profile of a drug to that of in vivo human and 62
are hence considered as the ‘gold standard’ for predicting in vivo metabolic pathways of drugs 63
[12]. Metabolic defects, restricted accessibility to suitable liver samples, unsuitability for 64
quantitative estimations, inability of the cells to proliferate, quick degradation of P450 65
enzyme activities during culture and the requirement for specific culturing conditions are 66
limitations of these in vitro models [10, 13].67
The concept of using microorganisms, and in particular Cunninghamella elegans, as 68
models of mammalian metabolism has been well documented [14-16]. It has been proved that 69
Cunninghamella has CYP509A1 enzymes that are synonymous to that involved in xenobiotic 70
detoxification in mammals [17] and can metabolize a wide variety of xenobiotics in a regio-71
and stereo-selective manner similar to mammalian enzyme systems [14, 15]. A recent review 72
on C. elegans reports that the fungus shows similarities with mammalian metabolism for a 73
wide variety of drugs, more than a hundred of them [15]. It is highly efficient in its production 74
of metabolites, especially from antidepressants, antibiotics, steroids, alkaloids and related 75
drugs [15]. The cultures of the fungus can be grown by transferring to new agar plates without 76
complexity adding to advantages of the model [18].77
The aim of the study was to elucidate the metabolite profile of (1-pentyl-1H-indol-3-78











methanone (JWH-073) and [1-(5-fluoropentyl)-1H-indol-3-yl]-1-naphthalenyl-methanone 80
(AM2201), three amino alkyl indoles with well-defined metabolic profiles, using the C. 81
elegans model and to compare with previously reported in vivo and in vitro data to examine82





JWH-018 and JWH-073 were synthesized in-house following previously reported methods 88
and characterized by mass spectrometry (MS) and nuclear magnetic resonance (NMR)89
spectroscopy with no evidence of cross contamination [24, 25]. AM2201 (purity 99.4%) was 90
obtained from the National Measurement Institute (North Ryde, NSW, Australia). Reference 91
standards of JWH-018 metabolites namely JWH-018 N-(4-hydroxypentyl), JWH-018 N-(5-92
hydroxypentyl) and JWH-018 N-pentanoic acid and JWH-073 metabolites namely JWH-07393
N-(3-hydroxybutyl), JWH-073 N-(4-hydroxybutyl) and JWH-073 N-butanoic acid were 94
obtained from PM separations (Capalaba, QLD, Australia). Reagent grade dichloromethane 95
and LC grade acetonitrile and methanol were obtained from Chemsupply (Gilman, SA, 96
Australia). Potato dextrose agar, glucose, peptone, and yeast extract were purchased from 97
Oxoid Australia (Adelaide, SA, Australia). 98
99
Microbial Culture and Biotransformation Conditions100
101
Cultures of C. elegans ATCC 10028b (Cryosite Ltd, South Granville, NSW, Australia) were 102
propagated on potato dextrose agar plates [26] at 27 °C for 5 days. The mycelia from five 103
plates were then transferred to 20 mL of sterile physiological saline solution and 104
homogenized for 5 min. Approximately 3 mL aliquots of the homogenate were used to 105
inoculate 250 mL Erlenmeyer flasks containing 100 ml of growth media. The cultures were 106










incubated for 48 h at 26 °C on an Infors HT Multitron rotary shaker (In vitro Technologies, 107
Noble Park North, VIC, Australia) operating at 180 rpm. After 48 h, 10 mg of JWH-018, 108
JWH-073 or AM2201 dissolved in 0.5 mL of methanol was added to the culture and 109
incubated for further 72 h [18]. Control experiments consisted of cultures without 110
cannabinoids and flasks containing only media and cannabinoid [27, 28].111
112
Extraction, Isolation, and Identification of Metabolites113
114
After 72 h of incubation, the contents of each flask, including the controls, were filtered 115
through Buchner funnel into a separating funnel and extracted with three aliquots of 116
dichloromethane (3 × 50 mL). The combined organic extracts were evaporated to dryness 117
under vacuum at 40 °C using a Buchi rotary evaporator (In vitro Technologies, Noble Park 118
North, VIC, Australia) and placed under high vacuum to remove traces of moisture. The 119
residue was dissolved in acetonitrile to prepare 1 mg/mL stock solution and was filtered 120
through 0.22 µM syringe filter before analysis. Cannabinoid parent drugs and metabolites 121
were chromatographically separated using an Agilent Zorbax Eclipse XDB-C18 analytical 122
column (150 × 4.6 mm, 5 μm). Mobile phases consisted of 0.1 % formic acid in water 123
(mobile phase A) and acetonitrile (mobile phase B). The gradient used consisted of 30 % B (0 124
to 2 min), linear gradient from 30 % B to 50 % B (2 to 5 min), 50 % B to 90 % B (5 to 30 min, 125
hold for 5 min) and 90 % B to 30 % B (35 to 40 min) run at 0.4 mL/min. MS data were 126
acquired on an Agilent 6490 Triple Quadrupole mass spectrometer with an electrospray 127
ionization source (ESI) source (positive ion mode), interfaced with an Agilent 1290 LC 128
system. Samples prepared were injected in 2 µL volume to obtain full scan and product ion 129
scan spectra. Product ion scan experiments were conducted on precursor ions that were 130
presumed to be metabolites based on the comparison of full scan spectra of the samples and 131
controls. A fragmentor voltage of 380 V with discrete collision energy of 10, 20, 30 and 40 eV 132
(for product ion scan) was applied. The scanning mass range was set at m/z 100-1000 (scan 133










time = 500 ms). The sheath gas temperature and flow were set to 250 °C and 11 L/min,134
respectively. The capillary and nozzle voltages were 3000 V and 1500 V, respectively.135
High resolution quadrupole Time-of-Flight mass spectrometry (HRQToFMS) 136
experiments were carried out on an Agilent 6510 Accurate Mass QToF Mass Spectrometer, 137
equipped with ESI source operated in positive ion mode, in order to determine accurate 138
masses of the metabolites. The LC system and conditions used were the same as above. The 139
following operation parameters were used: injection volume 2µL (full scan) and 10 µL140
(product ion scan); capillary voltage 3500 V; nebulizer pressure 40 psi (275790 Pascal); 141
drying gas 10.0 L/min; gas temperature 350 °C; fragmentor voltage 160 V; collision energy142
10, 20 and 40 eV; skimmer voltage 60 V. HRQToFMS accurate mass spectra were recorded143
across the range from m/z 100 to m/z 1000. The mass axis was calibrated using the mixture 144
provided by the manufacturer over the m/z 50-3200 range. A second orthogonal sprayer with a 145
reference solution was used as a continuous calibration using the following reference masses: 146
m/z 121.0509 and m/z 922.0098. The chromatographic conditions and column used were same 147
as described above. The controls were subjected to the same analysis. Analysis of the 148
chromatographic and mass spectrometric data was conducted using MassHunter Workstation 149
Software Qualitative Analysis (version B.06.00, Agilent). Peaks present in the fungus sample, 150
but not in the controls, were manually identified and their fragmentation patterns and accurate 151
masses were examined to identify the metabolites. The signal-to-noise ratio of all the 152




Fig. 1 shows the product ion mass spectra of JWH-018, JWH-073 and AM2201 and their 157
fragmentation patterns. These fragmentation patterns were used as a basis for determining the 158
structures of fungal metabolites of each drug as follows. The presence of a product ion at m/z159










155 in a mass spectrum of a metabolite indicates that the naphthalene moiety of the 160
metabolite has not been altered. If the ion at m/z 155 is absent, it suggests that the naphthalene 161
moiety has undergone modification such as hydroxylation, dihydroxylation or dihydrodiol. 162
The type of modification was deduced by the difference between the amu of the product ion 163
of the parent drugs, i.e. m/z 155, and that of the product ion of the metabolite such as m/z 171 164
or m/z 189. A difference of 16 amu (m/z 171 – m/z 155) indicates an addition of an oxygen 165
atom and hence the metabolite is considered to have undergone hydroxylation. Similarly, a 166
difference of 34 amu (m/z 189 – m/z 155) suggests a formation of dihydrodiol. Product ions 167
originating from other parts of metabolites, such as indole moiety or alkyl side chain, were 168
analysed in the same way to deduce the whole structures of metabolites. The product ion mass 169
spectra and their corresponding proposed fragmentation patterns of the most abundant 170
metabolite for each drug (Ma15 for JWH-018, Mb13 for JWH-073 and Mc25 for AM2201) 171
are shown in Fig. 1, illustrating the application of the above described approach in metabolite 172
identification.173
Overlaid extracted ion chromatograms of all the metabolites for each drug are shown 174
in Fig. 2. The majority of phase I metabolites after incubation with C. elegans were oxidation 175
products for all three drugs. In particular, hydroxylation was the most common transformation. 176
Phase II metabolites due to glucosidation and sulfation were only detected for AM2201. The 177
chromatograms of the control cultures without cannabinoids showed no metabolites or 178
substrate present; those of the control flasks containing media and cannabinoid showed only 179
the presence of the substrate. Metabolite identification was further supported by accurate 180
mass data obtained from the high resolution quadrupole Time-of-Flight mass spectrometry 181














Twenty one phase I metabolites (Ma1 – Ma21) were detected (Fig. 2A). Table 1 in Ref [29]186
lists all metabolites with suggested biotransformation, retention time, observed accurate mass, 187
formula and major product ions. Table 2 in Ref [29] tabulates the key diagnostic product ions 188
and their tentative structures used in elucidating the biotransformation pathways.189
Hydroxylation, dihydroxylation, carboxylation, dihydrodiol formation, dehydrogenation, 190
ketone formation, combinations of some of these transformations, and dihydrodiol formation 191
with N-dealkylation were observed. Phase II metabolites were not detected. Proposed 192
metabolic pathway is given in Fig. 3. Hydroxylation and dihydroxylation were the most 193
common transformations. The presence of the metabolites JWH-018 N-(4-hydroxypentyl) 194
(Ma15), JWH-018 N-(5-hydroxypentyl) (Ma14) and JWH-018 N-pentanoic acid (Ma13) was195
confirmed by comparison with reference standards on retention time and product ion 196
spectrum. The peak to the left of Ma13 in (a) has a m/z 372, but was found not to be a 197
carboxylic acid metabolite based on the product ions. Mass errors of all metabolites in 198
comparison with the calculated exact mass of proposed structures were all within 1.6 ppm.199
Comparison of metabolites obtained from C. elegans incubation in the present study with 200
those obtained from human urine, human liver microsomes and rat urine samples in the 201
literature is shown in Table 1. The majority of human urine metabolites reported in the 202




The metabolic transformation of JWH-073 was similar to that of JWH-018 except that there 207
were fewer (seventeen, Mb1-Mb17) metabolites detected. Table 3 in Ref [29] lists all 208
metabolites with suggested biotransformation, retention time, observed accurate mass, 209
formula and diagnostic product ions. Table 4 in Ref [29] tabulates the key diagnostic product 210
ions and their tentative structures used in elucidating the biotransformation pathways.211










Hydroxylation, dihydroxylation, carboxylation, dihydrodiol formation, dehydrogenation, 212
ketone formation, combinations of some of these transformations, and dihydrodiol formation 213
with N-dealkylation were observed. Phase II metabolites were not detected.  Proposed 214
metabolic pathway is given in Fig. 4. Hydroxylation was the most common transformation. 215
The presence of the metabolites JWH-073 N-(3-hydroxybutyl) (Mb13), JWH-073 N-(4-216
hydroxybutyl) (Mb12) and JWH-073 N-butanoic acid (Mb11) was confirmed by comparison 217
with reference standards on retention time and product ion spectrum. Mass errors of all 218
metabolites in comparison with the calculated exact mass of proposed structures were all 219
within 2.6 ppm. Comparison of metabolites obtained from C. elegans incubation in the 220
present study with those obtained from human urine and human liver microsomes samples in 221
the literature is shown in Table 2. Hydroxylation (human urine and human liver microsomes) 222





The biotransformation of AM2201 was similar to the other two drugs, but produced extra 228
metabolites including phase II metabolites. Forty eight phase I and II metabolites (Mc1-229
Mc48) were detected. Table 5 in Ref [29] lists all metabolites with suggested 230
biotransformation, retention time, observed accurate mass, formula and diagnostic product 231
ions. Table 6 in Ref [29] tabulates the key diagnostic product ions and their tentative 232
structures used in elucidating the biotransformation pathways. Hydroxylation, 233
dihydroxylation, trihydroxylation, oxidative defluorination, dihydrodiol formation, ketone 234
formation, N-dealkylation, defluorination and demethylation were observed either alone or in 235
combination. Glucosidation of hydroxy and dihydroxy metabolites and sulfation of dihydroxy 236
metabolites were detected as Phase II transformation. Although the retention of the sulfate 237










metabolites on the C18 column used appears unusually long, similar observations were 238
reported previously when the sulfate conjugates had a longer retention than the unconjugated 239
metabolites [28]. In contrast, glucuronidation was not observed. This lack of detection of 240
glucuronides is less likely due to the extraction conditions as the similarly polar glucoside 241
metabolites were successfully extracted and detected. Fig. 5 depicts the proposed metabolic 242
pathways of AM2201 by C. elegans. Hydroxylation and dihydroxylation were the most 243
common transformations. The presence of JWH-018 N-(5-hydroxypentyl) (Mc34) and JWH-244
018 N-pentanoic acid (Mc33) metabolites was confirmed by comparison with reference 245
standards on retention time and product ion spectrum. Mass errors of all metabolites in 246
comparison with the calculated exact mass of proposed structures were all within 1.4 ppm. 247
Comparison of metabolites obtained from C. elegans incubation in the present study with 248
those obtained from human urine, human postmortem heart blood, human liver microsomes 249
and rat urine samples in the literature is shown in Table 3. The majority of human urine 250
metabolites reported in the literature were detected in the fungus sample including JWH-018 251
N-(5-hydroxypentyl), JWH-018 N-pentanoic acid and AM2201 hydroxy metabolites.252
AM2201 is a fluorinated analogue of JWH-018 at the terminal carbon of the pentyl 253
side chain. Hence, in addition to the types of transformation observed for JWH-018 and JWH-254





The metabolic transformation of JWH-018, JWH-073 and AM2201 by C. elegans was similar 260
to one another as they are closely related structural analogues. The types of metabolic 261
transformation detected were identical for JWH-018 and JWH-073, and they are 262
carboxylation, dehydrogenation, dihydrodiol formation, dihydrodiol with hydroxylation, 263










dihydrodiol with ketone formation, dihydrodiol with N-dealkylation, dihydroxylation, and 264
hydroxylation, ketone formation, ketone formation with hydroxylation. AM2201 showed all 265
the transformation except carboxylation, dehydrogenation, and ketone formation with 266
hydroxylation. AM2201 underwent additional transformation including defluorination and 267
oxidative defluorination, unique to compounds with a fluorine atom, as well as phase II268
metabolism including glucosidation and sulfation. Due to oxidative defluorination, some of 269
the AM2201 metabolites are the same as JWH-018 metabolites: Mc4 and Ma2, Mc33 and 270
Ma13, Mc34 and Ma14. Mc23 and Mc28 also matched well with Ma6 and Ma8, respectively, 271
on both retention times and fragmentation patterns. Mc21, on the other hand, was a structural 272
isomer of Ma7. The number of metabolites and metabolic transformation observed for 273
AM2201 was higher than that for JWH-018 and JWH-073, likely because AM2201 has a 274
fluorine atom enabling additional metabolic pathways.275
Comparison of the fungus metabolites from the present study with human 276
metabolites reported in the literature shows good agreement. Out of the twelve kinds of 277
human urine metabolites reported in the literature for JWH-018, eight metabolite types were 278
also detected among the C. elegans metabolites (Table 1), including the major human urine 279
metabolites, namely N-(4-hydroxypentyl), N-pentanoic acid and N-(5-hydroxypentyl) 280
metabolites. Minor human urine metabolites [30] such as demethylation with carboxylation 281
(JWH-073 N-butanoic acid), dihydrodiol formation with dihydroxylation, N-dealkylation with282
hydroxylation and trihydroxylation metabolites were not observed using this model.283
For JWH-073, all the reported human urine and human liver microsomes metabolites, 284
i.e. hydroxylated and carboxylated metabolites, were observed in the C. elegans sample285
(Table 2). Compared to JWH-018 metabolites, very few have been reported as human urine or 286
human liver microsomes metabolites. This may be because the detection of only the major 287
metabolites were possible as the concentration of JWH-073 in the herbal products is usually 288
low [31]. In any case, the fungus demonstrated the ability to produce the major human 289











Among the ten human urine or human postmortem heart blood metabolites reported 291
for AM2201, six metabolites were generated by the fungus (Table 3). Most importantly, these 292
include the major human urine metabolites, JWH-018 N-(5-hydroxypentyl) and JWH-018 N-293
pentanoic acid metabolites [5], as well as JWH-018 N-(5-hydroxypentyl)-dihydrodiol, 294
AM2201 hydroxy, AM2201 dihydroxy and AM2201 dihydrodiol metabolites. The four 295
human urine metabolites that were not found in the fungus sample are N-dealkylation, JWH-296
018 N-(4-hydroxypentyl), JWH-073 N-butanoic acid and JWH-073 N-(4-hydroxybutyl) 297
metabolites. The disagreement between the fungus and the human urine metabolites, however, 298
may not be as significant. While JWH-018 N-(4-hydroxypentyl) metabolite was detected by 299
Jang et al. [32], Hutter et al. [5] did not find its presence in authentic urine samples nor in 300
self-administered urine samples. This may be such that JWH-018 N-(4-hydroxypentyl) 301
metabolite detected by Jang et al. might come from unreported consumption of JWH-018 by 302
the drug abusers. Also, despite the fact that JWH-073 metabolites were not observed in the 303
present study, the fungus produced JWH-073 itself, suggesting the possibility that it can 304
produce JWH-073 N-butanoic acid and JWH-073 N-(4-hydroxybutyl) metabolites if 305
incubated longer. With regards to human postmortem heart blood metabolites, it is interesting 306
to note that the reported metabolites are JWH-018 N-(5-hydroxypentyl), JWH-018 N-307
pentanoic acid and AM2201 N-(4-hydroxypentyl) metabolites and that the former two 308
metabolites are the most abundant as with human urine metabolites [33]. Therefore, the 309
fungus metabolites of AM2201 were consistent with not only human urine but also human 310
postmortem heart blood metabolites.311
Previously, the detection of JWH-018 itself as a metabolite of AM2201 has not been 312
reported although JWH-018 metabolites, such as JWH-018 N-(5-hydroxypentyl) and JWH-313
018 N-pentanoic acid, derived from oxidative defluorination have been reported. If JWH-018 314
can be formed as a metabolite by humans, it would present difficulty in distinguishing 315










AM2201 abusers from those who ingested both JWH-018 and AM2201. However, in a self-316
experiment where one of the authors ingested pure AM2201, the absence of JWH-018 N-(4-317
hydroxypentyl) metabolite, a major human metabolite of JWH-018, was reported in both 318
serum and urine samples [5]. This suggests that oxidative defluorination is the only pathway 319
to JWH-018 metabolites in humans and that if JWH-018 is formed at all, the concentration is 320
likely to be so low that it has virtually no effects on production of its metabolites.321
Unlike JWH-018 and JWH-073, phase II metabolites of AM2201 were also detected 322
in the fungus sample. However, glucuronides, which were determined to be the major phase II323
human urine metabolites [34], were not observed. Instead, glucosides and sulfates were found. 324
A previous study on drug metabolism by C. elegans showed that glucosides and sulfates were 325
formed for the drugs whose main phase II human and equine metabolites are sulfates and 326
glucuronides [28]. Although C. elegans has been reported to have the ability to produce 327
glucuronides [35], its capacity to produce glucuronides may be limited and therefore the 328
fungus is not suitable for producing the human phase II metabolites of synthetic cannabinoids, 329
whose main phase II metabolites are reported to be glucuronides [34, 36]. The cause for more 330
extensive metabolism observed for AM2201 is unknown. 331
In the present study, the incubation time was not optimised to obtain the best 332
metabolic profiles that mimic human metabolism in terms of the quantity (measured by peak 333
area) of the metabolites formed. Under the conditions reported here, however, JWH-018 N-(4-334
hydroxypentyl) metabolite (Ma15) and JWH-073 N-(3-hydroxybutyl) metabolite (Mb13) 335
were found to be the most abundant metabolite for JWH-018 and JWH-073, respectively, 336
consistent with human metabolism. On the other hand, carboxy metabolites (Ma13, Mb11), 337
were present in a relatively lower amount in the fungal system. With AM2201, the most 338
abundant metabolite was a dihydrodiol metabolite (Mc25), while the abundance of human 339
metabolites JWH-018 N-(5-hydroxypentyl) (Mc34) and JWH-018 N-pentanoic acid (Mc33) 340
was relatively low. Two limitations for using peak area as the quantity of the metabolites in 341










these experiments should be noted: different metabolites may have significant differences in 342
extraction recoveries resulting in a different ratio of metabolites observed by mass 343
spectrometry from the actual ratio in the sample and mass spectrometric responses can be 344
different for each metabolite due to different ionisation efficiencies.345
Metabolism study is important not only for drug testing purposes by Police and 346
hospital scientists but also for understanding pharmacology of the new designer drugs. 347
However, currently the identification of metabolites of synthetic cannabinoids is largely 348
relying on the analysis by mass spectrometry and thus the exact structures of metabolites are 349
inconclusive without the use of reference standards. Analysis of metabolites by nuclear 350
magnetic resonance spectroscopy after isolating them will provide more concrete structural 351
elucidation, but this is usually limited by the low amount of metabolites obtained by the 352
common models such as human hepatocytes, human liver microsomes or rats. With C. 353
elegans, it is easy to scale up the incubation and hence obtain a large amount of metabolites 354
[15], indicating the potential for isolation and purification of new synthetic cannabinoid355




Cunninghamella elegans produced a large number of metabolites of JWH-018, JWH-073 and 360
AM2201. Although the fungus cannot be reliable to produce phase II metabolites consistent 361
with humans, it has demonstrated its ability to form the reported major human phase I362
metabolites of the investigated synthetic cannabinoids. Therefore, the fungus has the potential 363
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Fig. 1. Product ion spectra (CE 20 eV) and the proposed fragmentation pathways for JWH-490
018, JWH-073, AM2201 and their most abundant metabolites (Ma15, Mb13 and Mc25).491
492
Fig. 2. Overlaid extracted ion chromatograms of all the metabolites identified in the fungus 493
sample of JWH-018 at m/z 306, 340, 356, 358, 372, 374, 376, 390, 392 (a); JWH-073 at m/z494
306, 326, 342, 344, 358, 360, 362, 376, 378 (b); and AM2201 at m/z 306, 328, 342, 358, 372, 495
374, 376, 388, 392, 394, 408, 410, 426, 472, 538, 554 (c). Only the major metabolites are 496
labelled for AM2201 (c).497
498
Fig. 3. Proposed metabolic pathway of JWH-018 in C. elegans.499
500
Fig. 4. Proposed metabolic pathway of JWH-073 in C. elegans.501
502
Fig. 5. Proposed metabolic pathway of AM2201 in C. elegans. Parentheses indicate 503
intermediate metabolites that were not detected in the study.504
505
506











Metabolites of JWH-018 after C. elegans incubation in comparison with metabolites from 507
other sources (human urine, human liver microsomes and rat urine) reported in literature, in 508
alphabetical order. Square brackets in the metabolites column indicate the corresponding 509
fungal metabolites in Fig. 3.510
Metabolites CE* HU* HLM* RU*
Carboxylation [Ma13] √ √ [20, 23, 30, 
37-39]
√ [19]




Dihydrodiol formation [Ma12] √ √ [37, 39] √ [19]
Dihydrodiol formation + dihydroxylation √ [37] √ [19]
Dihydrodiol formation + hydroxylation [Ma2, 
Ma3]
√ √ [37, 39] √ [19]
Dihydrodiol formation + ketone formation [Ma4, 
Ma5]
√
Dihydrodiol formation + N-dealkylation [Ma1] √ √ [37] √ [19]
Dihydroxylation [Ma6 – Ma9, Ma11] √ √ [20, 23, 37, 
39]
√ [19]
Hydroxylation [Ma14 – Ma16, Ma19, Ma20] √ √ [20, 23, 30, 
37-39]
√ [19, 23]
Ketone formation [Ma17, Ma18] √ √ [37] √ [19]
Ketone formation + hydroxylation [Ma10] √ √ [37] √ [19]
N-dealkylation √ [19] √ [20]
N-dealkylation + hydroxylation √ [20, 37, 39] √ [19] √ [20]
Trihydroxylation √ [23, 37] √ [19]
* Abbreviations: CE, Cunninghamella elegans; HU, human urine; HLM, human liver microsomes; RU, rat urine.511
512
513











Metabolites of JWH-073 after C. elegans incubation in comparison with metabolites from 514
other sources (human urine and human liver microsomes) reported in literature, in 515
alphabetical order. Square brackets in the metabolites column indicate the corresponding 516
fungal metabolites in Fig. 4.517
Metabolites CE* HU* HLM*
Carboxylation [Mb11] √ √ [38]
Dehydrogenation [Mb17] √
Dihydrodiol formation [Mb8] √
Dihydrodiol formation + hydroxylation [Mb2, Mb3] √
Dihydrodiol formation + ketone formation [Mb4] √
Dihydrodiol formation + N-dealkylation [Mb1] √
Dihydroxylation [Mb5 – Mb7] √
Hydroxylation [Mb12, Mb13, Mb15, Mb16] √ √ [20, 38] √ [23]
Ketone formation [Mb14] √
Ketone formation + hydroxylation [Mb9, Mb10] √
* Abbreviations: CE, Cunninghamella elegans; HU, human urine; HLM, human liver microsomes.518
519
520











Metabolites of AM2201 after C. elegans incubation in comparison with metabolites from 521
other sources (human urine, human postmortem heart blood, human liver microsomes and rat 522
urine) reported in literature, in alphabetical order. Square brackets in the metabolites column 523
indicate the corresponding fungal metabolites in Fig. 5.524
Metabolites CE* HU* HPHB* HLM* RU*
Defluorination (JWH-018) [Mc48] √
Defluorination + Demethylation (JWH-073) 
[Mc47]
√
Defluorination + hydroxylation (JWH-018 N-(4-
hydroxypentyl))
√ [32]
Dihydrodiol formation [Mc25, Mc30] √ √ [34] √ [34]
Dihydrodiol formation + dihydroxylation [Mc9] √
Dihydrodiol formation + hydroxylation [Mc5, 
Mc6]
√
Dihydrodiol formation + ketone formation [Mc10] √
Dihydrodiol formation + N-dealkylation [Mc1] √
Dihydroxylation [Mc2, Mc3, Mc7, Mc13, Mc16, 
Mc17, Mc19, Mc22, Mc24, Mc27, Mc29, Mc31, 
Mc32, Mc38, Mc42, Mc46]
√ √ [34] √ [34]
Hydroxylation [Mc12, Mc14, Mc35 – Mc37, Mc39 
– Mc41, Mc44, Mc45]
√ √ [5, 32, 
34, 40]
√ [33] √ [33, 
34]
√ [32]
Ketone formation [Mc43] √
N-dealkylation √ [34] √ [34]
Oxidative defluorination (JWH-018 N-(5-
hydroxypentyl)) [Mc34]
√ √ [5, 32, 
34]
√ [33] √ [33, 
34]
√ [32]
Oxidative defluorination + dihydrodiol formation 
(JWH-018 dihydrodiol-hydroxy) [Mc4]
√ √ [34] √ [34]
Oxidative defluorination + hydroxylation (JWH-
018 dihydroxy) [Mc15, Mc18, Mc21, Mc23, 
Mc28]
√
Oxidative defluorination to carboxylic acid (JWH-
018 N-pentanoic acid) [Mc33]
√ √ [5, 32, 
34]
√ [33] √ [33, 
34]
√ [32]
Oxidative defluorination to carboxylic acid + 
decarboxylation + carboxylation (JWH-073 N-
butanoic acid)
√ [5, 32] √ [32]
Oxidative defluorination to carboxylic acid + 
decarboxylation + hydroxylation (JWH-073 N-(4-
hydroxybutyl)
√ [5]
Oxidative defluorination to carboxylic acid + 
hydroxylation [Mc20, Mc26]
√
Trihydroxylation [Mc8, Mc11] √
* Abbreviations: CE, Cunninghamella elegans; HU, human urine; HLM, human liver microsomes; RU, rat urine.525
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Fig. 1. Product ion spectra (CE 20 eV) and the proposed fragmentation pathways for JWH-018, 








































Fig. 2. Overlaid extracted ion chromatograms of all the metabolites identified in the fungus sample of 
JWH-018 at m/z 306, 340, 356, 358, 372, 374, 376, 390, 392 (a); JWH-073 at m/z 306, 326, 342, 344, 
358, 360, 362, 376, 378 (b); and AM2201 at m/z 306, 328, 342, 358, 372, 374, 376, 388, 392, 394, 408, 
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Fig. 3. Proposed metabolic pathway of JWH-018 in C. elegans. 
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Fig. 4. Proposed metabolic pathway of JWH-073 in C. elegans. 
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Fig. 5. Proposed metabolic pathway of AM2201 in C. elegans. Parentheses indicate 
intermediate metabolites that were not detected in the study. 
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